AbbVie says FDA reviews Skyrizi subcutaneous induction dosing for Crohn’s disease
ABBV•AbbVie said the FDA and EMA are reviewing subcutaneous induction dosing of Skyrizi for Crohn’s disease. Phase 3 AFFIRM data showed week 24 endoscopic remission of 35.8% with Skyrizi versus 9.1% with placebo.
1. Regulatory review
AbbVie said subcutaneous induction dosing for its Crohn’s disease drug Skyrizi is under review by the FDA and EMA. Phase 3 AFFIRM data showed week 24 endoscopic remission of 35.8% on Skyrizi compared with 9.1% on placebo.
